Abstract | OBJECTIVE: RESULTS: The percentage changes in lumbar spine bone mineral density (BMD) after 6 months of the therapy were -10.5% +/- 0.8% in the alfacalcidol group, but only -2.1% +/- 1.2% in the combined group. The rate of bone loss in the lumbar spine was significantly lower in the combined group than in the alfacalcidol group at 6 months. At 12 months of treatment, the percentage change in lumbar spine BMD was increased by 1.7% +/- 1.4% in the combined group, but decreased by 9.9% +/- 1.9% in the alfacalcidol group; the difference was significant. Bone fracture occurred at 12 months or later in 4 patients of the alfacalcidol groups, but not in the combined group, even at up to 18 months. CONCLUSION:
|
Authors | Yosuke Okada, Masao Nawata, Shingo Nakayamada, Kazuyoshi Saito, Yoshiya Tanaka |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 35
Issue 11
Pg. 2249-54
(Nov 2008)
ISSN: 0315-162X [Print] Canada |
PMID | 19031508
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Bone Density Conservation Agents
- Glucocorticoids
- Hydroxycholecalciferols
- Prednisolone
- alfacalcidol
- Alendronate
|
Topics |
- Adolescent
- Adult
- Alendronate
(administration & dosage)
- Autoimmune Diseases
(drug therapy)
- Bone Density
(drug effects)
- Bone Density Conservation Agents
(administration & dosage)
- Drug Therapy, Combination
- Female
- Fractures, Bone
(chemically induced, prevention & control)
- Glucocorticoids
(administration & dosage, adverse effects)
- Humans
- Hydroxycholecalciferols
(administration & dosage)
- Middle Aged
- Osteoporosis
(chemically induced, prevention & control)
- Prednisolone
(administration & dosage, adverse effects)
- Premenopause
- Young Adult
|